Podcast appearances and mentions of Justin F Gainor

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches for Patients with NSCLC and Other Actionable Genomic Alterations — Justin F Gainor, MD CME information and select publications

Featuring perspectives from Dr Justin F Gainor and Dr Karen Reckamp, including the following topics: Introduction: Bringing Research into Practice (0:00) EGFR Activating Mutations (14:01) Exon 20 Insertion Mutations (38:06) MET Exon 14 Alterations (41:49) HER2 Mutations and Overexpression (50:27) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/TargetedLung).

Featuring perspectives from Drs Justin Gainor, Corey Langer, Luis Paz‑Ares, Heather Wakelee, Jared Weiss and Helena Yu, including the following topics: Introduction (0:00) Incorporation of immunotherapeutic strategies into the management of nonmetastatic non-small cell lung cancer (NSCLC) — Heather Wakelee, MD (3:18) Contemporary treatment for localized and metastatic NSCLC with EGFR mutations — Helena Yu, MD (33:46) Research advances shaping the current and future treatment of metastatic NSCLC with ALK rearrangements, ROS1 rearrangements or RET fusions — Justin F Gainor, MD (58:03) Targeting alterations in MET, HER2, KRAS and other oncogenes in NSCLC — Jared Weiss, MD (1:19:24) Current and future management of metastatic NSCLC without a targetable tumor mutation — Corey J Langer, MD (1:42:57) Current treatment paradigm for small cell lung cancer — Luis Paz-Ares, MD, PhD (2:07:58) CME information and select publications

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, gynecologic cancers and lung cancer. Featuring perspectives from Drs Thomas A Abrams, John N Allan, Deborah K Armstrong, Arjun Balar, Virginia F Borges, Harold J Burstein, Robert Dreicer, Justin F Gainor, J Randolph Hecht, Corey J Langer, Krishnansu S Tewari, and Sonali M Smith, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, gynecologic cancers and lung cancer. Featuring perspectives from Drs Thomas A Abrams, John N Allan, Deborah K Armstrong, Arjun Balar, Virginia F Borges, Harold J Burstein, Robert Dreicer, Justin F Gainor, J Randolph Hecht, Corey J Langer, Krishnansu S Tewari, and Sonali M Smith, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Courtney D DiNardo, Robert Dreicer, Justin F Gainor, Sara Hurvitz, Ian E Krop, John M Pagel, Alexander Perl, Daniel P Petrylak, Philip A Philip, Paul G Richardson, Mitchell R Smith, Prof Eric Van Cutsem and Drs Peter Voorhees and Heather Wakelee, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Courtney D DiNardo, Robert Dreicer, Justin F Gainor, Sara Hurvitz, Ian E Krop, John M Pagel, Alexander Perl, Daniel P Petrylak, Philip A Philip, Paul G Richardson, Mitchell R Smith, Prof Eric Van Cutsem and Drs Peter Voorhees and Heather Wakelee, moderated by Dr Neil Love.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.

Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.